GlassScriptPhysician profile
Amanda Morris
NPI 1548622590
$4,816.49
in general payments reported to CMS, 2019-2025
38 companies · $583 in 2025
The $583 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,268 · 2022: $1,489 · 2023: $868 · 2024: $610 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.84 | 2021-2025 | |
| Lilly USA, LLC | $595.65 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $298.51 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $286.41 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $211.16 | 2021-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $206.97 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Merz North America, INC. | $198.63 | 2022 | |
| Pfizer INC. | $184.45 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $183.12 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.75 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $138.52 | 2021-2023 | Verquvo, Steglatro, Steglujan |
| Antares Pharma, INC. | $137.82 | 2024-2025 | Xyosted |
| Rhythm Pharmaceuticals, INC. | $131.44 | 2023 | Imcivree |
| Axsome Therapeutics, INC. | $103.72 | 2023-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $100.94 | 2022-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.